We warmly congratulate our PhD student Andrej Feješ on his prestigious publication in the journal Cell Metabolism, which was published during his internship at the University of Gothenburg (Sweden) under the supervision of Dr. Linda Engström Ruud. Semaglutide, a GLP-1R agonist used for obesity treatment, reduces food intake and body weight by reactivating dorsal vagal complex neurons. Ablation of area postrema and nucleus of the solitary tract neurons (Adcyap1+) largely reverses semaglutide’s effects on energy balance, suggesting that targeting semaglutide-responsive Adcyap1+ neurons could improve future anti-obesity treatments.